Benralizumab

Benralizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD125
Clinical data
Pronunciation	ben" ra liz' ue mab
Trade names	Fasenra
AHFS/Drugs.com	Monograph
MedlinePlus	a618002
License data	US DailyMed: Benralizumab;
Pregnancy; category	AU: B1;
Routes of; administration	Subcutaneous
ATC code	R03DX10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1044511-01-4 ;
DrugBank	DB12023 ;
ChemSpider	none;
UNII	71492GE1FX;
KEGG	D09874 ;
Chemical and physical data
Formula	C6492H10060N1724O2028S42
Molar mass	146056.45 g·mol−1
	(what is this?) (verify)

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca.

Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016. It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma. It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.

Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.